Adamis Pharmaceuticals has signed an agreement to completely acquire 3M Company's MMM -0.36% Taper Dry Powder Inhaler (DPI) technology. Additionally, the company has entered into an agreement to exclusively license the platform technology ...
Tags: Adamis Pharmaceuticals, Dry Powder
Swiss drugmaker Novartis has announced that once-daily dual bronchodilator, Ultibro Breezhaler (QVA149), has achieved positive CHMP opinion for the treatment of chronic obstructive pulmonary disease (COPD). Ultibro Breezhaler was ...
GlaxoSmithKline (GSK) and Theravance have withdrawn license application for the use of inhaled drug fluticasone furoate (FF) and vilanterol (VI), with proposed brand name of Relvar Ellipta, as treatment for chronic obstructive pulmonary ...
Tags: Japan, GSK, Relvar License
AstraZeneca has agreed to purchase California-based respiratory medication developer, Pearl Therapeutics, in a deal with a total potential cost of up to $1.15bn. As per the definitive agreement signed between both the parties, AstraZeneca ...
Tags: AstraZeneca, Pearl Therapeutics
GlaxoSmithKline (GSK) and Theravance have announced the FDA approval of Breo Ellipta as maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD) patients. The inhaled long-term, once-daily maintenance ...
Tags: GSK, Theravance, Copd Therapy
GlaxoSmithKline (GSK) has submitted a new drug application (NDA) to the US FDA for umeclidinium bromide (UMEC) monotherapy 62.5mcg to treat chronic obstructive pulmonary disease (COPD). The investigational once-daily UMEC, administered ...
Tags: GlaxoSmithKline, FDA Approval, chronic obstructive pulmonary disease
Forest Laboratories and Almirall have reported positive results from the ACLIdinium/FORMoterol fumarate combination for Investigative use in the treatment of moderate to severe COPD (ACLIFORM/COPD) Phase III study. ACLIFORM/COPD is the ...
ResMed has launched its home variable positive airway pressure (VPAP) device in the US for the treatment of respiratory disorders such as chronic obstructive pulmonary disease (COPD). Used at night, VPAP COPD device helps the patients to ...
Tags: COPD Treatment Device, ResMed
GSK and Theravance have announced the submission of a regulatory application for Anoro Ellipta (UMEC/VI) (62.5/25mcg and 125/25mcg doses) in Japan. UMEC/VI combines a long-acting muscarinic antagonist (LAMA) GSK573719 or umeclidinium ...
Asmacure has commenced phase 1/2 trial of ASM-024 dry powder for inhalation (DPI) formulation with multi-functional mechanism of action with nicotinic and muscarinic effects. In pre-clinical asthma models ASM-024 exhibited the ...
Tags: Asmacure, Dry Powder, Inhalation
US-based biopharmaceutical company Spring Bank Pharmaceuticals has closed a $10.5m Series A financing round from Brock Securities with Gilford Securities as a participator. The firm is planning to invest the fund in its Phase I clinical ...
Wireless remote monitoring devices will be used by more than 1.8 million people worldwide in four years, representing a six-fold increase in adoption of telehealth technology, according to a new study by InMedica, part of research firm IHS. ...
Celerion has added a bronchoscopy suite in the Belfast, Northern Ireland, UK facility, to expand its respiratory capabilities. The company can perform bronchoalveolar lavage (BAL) using study participants from its database. The ...
GlaxoSmithKline and Theravance have announced the MAA submission for Anoro in Europe for patients with chronic obstructive pulmonary disease (COPD). The COPD therapy, administered using the ELLIPTA inhaler, is a combination of GSK573719 ...
Tags: GlaxoSmithKline, COPD therapy, chronic obstructive pulmonary disease
GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for the investigational once-daily LAMA/LABA combination medicine, umeclidinium bromide (UMEC/VI), to treat chronic obstructive pulmonary disease (COPD) ...
Tags: GlaxoSmithKline, regulatory application, Medicine, FDA